Purpose <p>Crohn’s disease is a heterogenous disease of the gastrointestinal tract. New treatments have emerged in the last few decades, which raises the question as to what the best treatment recommendations would be for patients with mild disease. We sought to integrate both historical treatment strategies with recent evidence to propose a comprehensive approach.</p> Recent Findings <p>Advanced therapies such as biologics and small molecules have been developed to treat Crohn’s disease, which could be useful in a top-down approach to treat even mild cases and prevent future complications.</p> Summary <p>While traditional approaches such as budesonide and sulfasalazine are efficacious in inducing and maintaining immune suppression in Crohn’s disease, strong consideration should be given for a top-down approach with advanced therapies such as infliximab. Selection of high-risk individuals would be important for advanced therapy. Future research should additionally include a focus on mild presentations of disease to determine if these advanced therapies would be appropriate first line therapeutic options, especially in patients who are diagnosed at a younger age.</p>